Funding for this research was provided by:
Swedish Orphan Biovitrum
Dova
Article History
Accepted: 5 June 2021
First Online: 23 June 2021
Declarations
:
: Medical writing support and literature search were provided by Michael R. Page, PharmD, RPh, Vaidehee Deshpande, PhD, and Sarah Bubeck, PhD of BioCentric, Inc. (Collingswood, NJ, USA). The development of this manuscript was supported by funding from Dova Pharmaceuticals, a Sobi company (Durham, NC, USA).
: JG: No relevant conflicts of interest. ML: No relevant conflicts of interest. JB: No relevant conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Authors contributed equally to the writing of the manuscript and provided extensive revisions.